Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

CD16/CD30 bispecific monoclonal antibodies can induce remissions of Hodgkin's disease
refractory to chemo-and radiotherapy. However, the development of human antimouse …

Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II dose escalation
trial with the NK-cell activating bispecific monoclonal antibody HRS-3/A9 which is directed …

In various clinical studies, Hodgkin's patients have been treated with anti-CD30
immunotherapeutic agents and have shown promising responses. One of the problems that …

Bispecific antibodies have been exploited both as cancer immunodiagnostics and as cancer
therapeutics, and have shown promise in several clinical trials in cancer imaging and …

A group of 15 patients with refractory Hodgkin′ s disease were treated in a phase I/II trial
with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is …

e18532 Background: CD30 is a validated tumor target that is expressed on both Hodgkin's
Lymphoma cells and some activated immune cells. To improve antibody-based therapies …

Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on
target cells and for surface markers on immune effector cells, have been shown (in vitro) to …

Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the
natural killer (NK)-cell–activating bispecific monoclonal antibody HRS-3/A9, which is …

Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb),
immune checkpoint inhibitors, chimeric antigen receptor T‐cell (CAR‐T), cytokine‐induced …